Developing New Medicines to Improve the
Lives of Patients Worldwide
We have a proven track record of successful pharmaceutical product development and approvals. We are proud to have developed and launched an innovative pharmaceutical product in markets around the world.
Learn more about our product.
We have a passion for cutting-edge science. At Sucampo, science is at the core of everything we do. We are committed to developing our own programs and partnering with others to incorporate new scientific knowledge to help best address the pressing health needs of our patients.
We work only with the best. Sucampo is made up of great people and great partners. We actively seek the top people to join our team.
Learn more about our career opportunities.
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.